Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy
Purpose Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and
the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt …
the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt …
Defining and treating high-grade B-cell lymphoma, NOS
High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …
Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population
W Alduaij, B Collinge, S Ben-Neriah… - Blood, The Journal …, 2023 - ashpublications.org
Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable
outcomes achieved with immunochemotherapy. However, outcomes of gene expression …
outcomes achieved with immunochemotherapy. However, outcomes of gene expression …
ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection?
GS Nowakowski, MS Czuczman - American Society of Clinical …, 2015 - ascopubs.org
Personalized therapy for the treatment of patients with cancer is rapidly approaching and is
an achievable goal in the near future. A substantial number of novel targets have been …
an achievable goal in the near future. A substantial number of novel targets have been …
Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma
D Ennishi, A Jiang, M Boyle, B Collinge… - Journal of Clinical …, 2019 - ascopubs.org
Purpose High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
(HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to …
(HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to …
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene …
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
[HTML][HTML] Prognostic factors for diffuse large B-cell lymphoma in the R (X) CHOP era
Background The introduction of rituximab (R) to conventional CHOP chemotherapy for newly
diagnosed diffuse large B-cell lymphoma (DLBCL) led to an unequivocal improvement in …
diagnosed diffuse large B-cell lymphoma (DLBCL) led to an unequivocal improvement in …
[HTML][HTML] Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
Using a Burkitt lymphoma-like gene expression signature, we recently defined a high-risk
molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B …
molecular high-grade (MHG) group mainly within germinal centre B-cell like diffuse large B …
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification …
Gene expression profiling (GEP) has stratified diffuse large B-cell lymphoma (DLBCL) into
molecular subgroups that correspond to different stages of lymphocyte development …
molecular subgroups that correspond to different stages of lymphocyte development …
[HTML][HTML] Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma
L Pedrosa, I Fernández-Miranda, D Pérez-Callejo… - Scientific reports, 2021 - nature.com
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is
associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative …
associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative …